{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:43:01Z","timestamp":1785426181212,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":5436,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2011]]},"DOI":"10.1186\/2110-5820-1-48","type":"journal-article","created":{"date-parts":[[2011,11,23]],"date-time":"2011-11-23T14:36:32Z","timestamp":1322058992000},"page":"48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Combination antibiotic therapy for community-acquired pneumonia"],"prefix":"10.1016","volume":"1","author":[{"given":"Jesus","family":"Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1186\/2110-5820-1-48_bb0010","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious diseases society of America\/American thoracic society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2004.05.010","article-title":"Etiology of community-acquired pneumonia treated in an ambulatory setting","volume":"99","author":"Marrie","year":"2005","journal-title":"Respir Med"},{"key":"10.1186\/2110-5820-1-48_bb0020","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1136\/thorax.56.4.296","article-title":"Study of community acquired pneumonia etiology (SCAPA) in adults admitted to hospital: implications for management guidelines","volume":"56","author":"Lim","year":"2001","journal-title":"Thorax"},{"key":"10.1186\/2110-5820-1-48_bb0025","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0163-4453(99)90043-9","article-title":"Evidence-based medicine: empiric antibiotic therapy in community acquired pneumonia","volume":"39","author":"Read","year":"1999","journal-title":"J Infect"},{"key":"10.1186\/2110-5820-1-48_bb0030","first-page":"589","article-title":"Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumonia in adults","volume":"11","author":"Weiss","year":"2004","journal-title":"Can Respir J"},{"key":"10.1186\/2110-5820-1-48_bb0035","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/CCM.0b013e318194b021","article-title":"PIRO score for community-acquired pneumonia: A new prediction rule for assessment of severity in intensive care unit patients with community-acquired pneumonia","volume":"37","author":"Rello","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/QCO.0b013e328343b70d","article-title":"Why should we measure bacterial load when treating community-acquired pneumonia?","volume":"24","author":"Waterer","year":"2011","journal-title":"Curr Opin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0045","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian infectious diseases society and the Canadian thoracic society; the Canadian community-acquired pneumonia working group","volume":"31","author":"Mandell","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0050","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1183\/09031936.99.13234999","article-title":"Risk factors for community-acquired pneumonia in adults: a population-based case-control study","volume":"13","author":"Almirall","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1186\/2110-5820-1-48_bb0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.amjmed.2010.06.027","article-title":"Treatment of community-acquired pneumonia in an ambulatory setting","volume":"124","author":"Butt","year":"2011","journal-title":"Am J Med"},{"key":"10.1186\/2110-5820-1-48_bb0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/2110-5820-1-48_bb0065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Bartlett","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0070","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archinte.160.10.1399","article-title":"Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from de Drug-Resistant Streptococcus pneumonia Therapeutic Working Group","volume":"160","author":"Heffelfinger","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1186\/2110-5820-1-48_bb0075","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community acquired-pneumonia in immunocompetent adults","volume":"37","author":"Mandell","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0080","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention","volume":"163","author":"Niederman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0085","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1001\/archinte.159.21.2562","article-title":"Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia","volume":"159","author":"Gleason","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1186\/2110-5820-1-48_bb0090","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1345\/aph.19174","article-title":"Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching UA community hospitals","volume":"34","author":"Dudas","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1186\/2110-5820-1-48_bb0095","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1378\/chest.119.5.1420","article-title":"Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states: 1993, 1995, and 1997","volume":"119","author":"Houck","year":"2001","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0100","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.161.15.1837","article-title":"Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia","volume":"161","author":"Waterer","year":"2001","journal-title":"Arch Int Med"},{"key":"10.1186\/2110-5820-1-48_bb0105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1086\/367541","article-title":"Addition of a macrolide to a \u03b2-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia","volume":"36","author":"Martinez","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0110","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1378\/chest.123.5.1503","article-title":"Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database","volume":"123","author":"Brown","year":"2003","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0115","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1164\/rccm.200311-1578OC","article-title":"Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteriemia","volume":"170","author":"Baddour","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0120","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10096-005-1295-9","article-title":"Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a \u03b2-lactam agent alone","volume":"24","author":"Garcia-Vazquez","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0125","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc3934","article-title":"The impact of empiric antimicrobial therapy with a \u03b2-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia","volume":"10","author":"Mortensen","year":"2006","journal-title":"Crit Care"},{"key":"10.1186\/2110-5820-1-48_bb0130","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1097\/01.CCM.0000266755.75844.05","article-title":"Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock","volume":"35","author":"CAPUCI Study Group","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0135","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1378\/chest.06-1426","article-title":"Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not fluoroquinolones","volume":"131","author":"Metersky","year":"2006","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0140","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1186\/2110-5820-1-48_bb0145","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/jac\/dkp088","article-title":"Impact of intravenous \u03b2-lactam\/macrolide versus \u03b2-lactam monotherapy on mortality in hospitalized patients with community-acquired pneumonia","volume":"63","author":"Tessmer","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1186\/2110-5820-1-48_bb0150","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s00134-009-1730-y","article-title":"Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia","volume":"36","author":"Mart\u00edn-Loeches","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0155","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S0149-2918(00)80059-4","article-title":"Effect of macrolides as part of initial empiric therapy on medical outcomes in community-acquired pneumonia","volume":"22","author":"Burgess","year":"2000","journal-title":"Clin Ther"},{"key":"10.1186\/2110-5820-1-48_bb0160","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10096-006-0183-2","article-title":"Addition of a macrolide to a \u03b2-lactam in bacteremic pneumococcal pneumonia","volume":"25","author":"Dwyer","year":"2006","journal-title":"Eur J Clin Microbiol Dis"},{"key":"10.1186\/2110-5820-1-48_bb0165","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s10096-005-0018-6","article-title":"Lack of effect of combination antibiotic therapy on mortality in patients with pneumococcal sepsis","volume":"24","author":"Harbarth","year":"2005","journal-title":"Eur J Clin Microbiol Dis"},{"key":"10.1186\/2110-5820-1-48_bb0170","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.128.1.172","article-title":"Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors","volume":"128","author":"Leroy","year":"2005","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1378\/chest.128.1.10","article-title":"Monotherapy in severe community-acquired pneumonia: is it worthy?","volume":"128","author":"Torres","year":"2005","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0180","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1128\/AAC.00006-07","article-title":"Comparison of \u03b2-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia","volume":"51","author":"Lodise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/2110-5820-1-48_bb0185","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1378\/chest.128.2.940","article-title":"The controversy of combination vs. monotherapy in the treatment of hospitalized community-acquired pneumonia","volume":"128","author":"Weiss","year":"2005","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0190","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1378\/chest.10-2371","article-title":"Antibiotic dosing in multiple organ dysfunction syndrome","volume":"139","author":"Ulldemolins","year":"2011","journal-title":"Chest"},{"key":"10.1186\/2110-5820-1-48_bb0195","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00134-010-1950-1","article-title":"Questions remain regarding mandatory use of macrolides in community-acquired pneumonia","volume":"36","author":"Westley","year":"2010","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0200","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/thx.51.2.179","article-title":"Multiple pathogens in adult patients admitted with community-acquired pneumonia a one year prospective study of 346 consecutive patients","volume":"51","author":"Lieberman","year":"1996","journal-title":"Thorax"},{"key":"10.1186\/2110-5820-1-48_bb0205","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/ajrccm.156.1.9612065","article-title":"Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells","volume":"156","author":"Takizawa","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0210","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/515199","article-title":"Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. The Canadian streptococcal study group","volume":"4","author":"Kaul","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1186\/2110-5820-1-48_bb0215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1128\/AAC.48.1.93-99.2004","article-title":"Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa","volume":"48","author":"Giamarellos-Bourboulis","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1186\/2110-5820-1-48_bb0220","first-page":"S40","article-title":"Macrolide therapy is associated with lower 30- and 90-day mortality in mechanically ventilated patients with severe sepsis","volume":"37","author":"Restrepo","year":"2011","journal-title":"Intensive Care Med"},{"key":"10.1186\/2110-5820-1-48_bb0225","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.47.3.1151-1153.2003","article-title":"Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumonia in vitro","volume":"47","author":"Lin","year":"2003","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2110-5820-1-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2110-5820-1-48\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025015286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025015286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2110-5820-1-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:18:24Z","timestamp":1776669504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025015286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011]]}},"alternative-id":["S2110582025015286"],"URL":"https:\/\/doi.org\/10.1186\/2110-5820-1-48","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2011]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination antibiotic therapy for community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/2110-5820-1-48","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Caballero and Rello; licensee Springer. 2011. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"48"}}